About Alzamend Neuro™, Inc.
Alzamend Neuro is an emerging biopharmaceutical company dedicated to supporting the full product development life cycle of treatment and cures to improve the lives of patients diagnosed with Alzheimer’s, other degenerative diseases and psychiatric disorders. Alzamend Neuro is currently advancing its lead therapeutic candidate, AL001, an ionic cocrystal of lithium that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer’s, into Phase 1 clinical trials in the fourth quarter of 2020. Our second therapeutic candidate, AL002, an adjuvant-free therapeutic vaccine intended for use as a treatment or prophylactic for patients diagnosed with Alzheimer’s, will advance into Phase 1 clinical trials in the first quarter of 2021. Additional programs are progressing in development.
The number of Americans projected to be living with Alzheimer’s disease by the year 2050
The number of Americans projected currently living with Alzheimer’s disease in 2019
Every 65 Seconds
The estimate how often someone in the United States develops Alzheimer’s disease
Leading cause of death in the U.S.
The estimated number of seniors that will die with Alzheimer’s disease or other dementia by 2050
Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans
The estimated cost in 2019 of Alzheimer’s disease to the United States.
The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends
The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found
The estimated number of Americans age 65 and over that are afflicted in 2019 with Alzheimer’s disease
Are 2 ½ times more likely than men to develop Alzheimer’s disease in the United States
Estimated number of Americans that will have Alzheimer’s disease or other form of dementia by 2050 if a treatment or cure is not found